A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy

被引:4
作者
Naik, Shailendra S. [1 ]
Vanidassane, Ilavarasi [2 ]
Dhamija, Ekta [1 ]
Sharma, Atul [2 ]
机构
[1] AIIMS, IRCH, Dept Radiodiag, New Delhi, India
[2] AIIMS, Dept Med Oncol, IRCH, New Delhi 110029, India
关键词
Chemotherapy; drug-induced encephalopathy; encephalopathy; 5-fluorouracil;
D O I
10.4103/ijri.IJRI_17_19
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
5-Fluorouracil (5-FU), a commonly used antimetabolite and antineoplastic agent, has been approved for the treatment of various cancers. It is associated with systemic side-effects such as gastrointestinal problems, neutropenia. 5-FU-related encephalopathy is very rarely reported. Imaging with computed tomography (CT) and magnetic resonance imaging (MRI) plays a key role in diagnosing and monitoring the changes. Since the prognosis of cerebral involvement is usually good if recognized and treated in time, the reporting radiologist and treating physician should be familiar with them. We present a rare case of 5-FU-induced encephalopathy that was diagnosed based on her clinical and MRI findings and managed successfully.
引用
收藏
页码:214 / 217
页数:4
相关论文
共 50 条
  • [1] Selective delivery of 5-fluorouracil (5-FU) to ip tissues using 5-FU microspheres in rats
    Hagiwara, A
    Sakakura, C
    Tsujimoto, H
    Imanishi, T
    Ohgaki, M
    Yamasaki, J
    Sawai, K
    Takahashi, T
    Fujita, T
    Yamamoto, A
    Muranishi, S
    Ikada, Y
    ANTI-CANCER DRUGS, 1997, 8 (02) : 182 - 188
  • [2] Fluorouracil (5-FU)-induced Cardiomyopathy
    Thalambedu, Nishanth
    Khan, Yasir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
  • [3] The herbal extract, Iberogast®, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis
    Wright, Tessa H.
    Yazbeck, Roger
    Lymn, Kerry A.
    Whitford, Eleanor J.
    Cheah, Ker Y.
    Butler, Ross N.
    Feinle-Bisset, Christine
    Pilichiewicz, Amelia N.
    Mashtoub, Suzanne
    Howarth, Gordon S.
    CANCER BIOLOGY & THERAPY, 2009, 8 (10) : 923 - 929
  • [4] Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs
    Roberts, WJ
    Sloan, KB
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) : 1028 - 1036
  • [5] Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects
    Mindt, Sonani
    Aida, Sihem
    Merx, Kirsten
    Mueller, Annette
    Gutting, Tobias
    Hedtke, Maren
    Neumaier, Michael
    Hofheinz, Ralf-Dieter
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2019, 57 (07) : 1012 - 1016
  • [6] A Case of 5-Fluorouracil Induced Encephalopathy
    Kwon, Kyung A.
    Kwon, Hyuk-Chan
    Kim, Min Chan
    Kim, Sung-Hyun
    Oh, Sung Yong
    Lee, Suee
    Kim, Hyo-Jin
    CANCER RESEARCH AND TREATMENT, 2010, 42 (02): : 118 - 120
  • [7] Intralesional 5-fluorouracil (5-FU) for the treatment of eyelid squamous cell carcinoma in 5 horses
    Pucket, J. D.
    Gilmour, M. A.
    EQUINE VETERINARY EDUCATION, 2014, 26 (06) : 331 - 335
  • [8] Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer
    Taïeb, J
    Artru, P
    Baujat, B
    Mabro, M
    Carola, E
    Maindrault, F
    Tournigand, C
    Krulik, M
    Louvet, C
    de Gramont, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) : 661 - 666
  • [9] Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer
    Ying, Li-Sha
    Yu, Jiang-Liu
    Lu, Xiao-Xiao
    Ling, Zhi-Qiang
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (02) : 414 - 422
  • [10] Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
    Taïeb, J
    Mitry, E
    Boige, V
    Artru, P
    Ezenfis, J
    Lecomte, T
    Clavero-Fabri, MC
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1192 - 1196